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Background: There is currently limited information regarding lung clearance index (LCI) and its response to treatment of pulmonary exacerbations
in CF. We aimed to examine the utility of LCI for assessing short term clinical response to IV antibiotic therapy in school-age children with CF.
Methods: Subjects experiencing exacerbations and hospitalised for IV antibiotics performed both multiple breath nitrogen washout (MBNW) and
spirometry on admission to hospital and prior to discharge.
Results: 27 patients (aged 6–20 years) had paired data for MBNW and spirometry. Mean LCI reduced from 12.18 to 11.65 (4.4%) by time of
discharge and FEV1 z-score improved from −3.05 to −2.86 (6.2%). Overall, LCI improved in n = 15 (55%) patients compared with n = 18 (67%)
where FEV1 improved.
Conclusions: In summary, these ﬁndings do not support the use of LCI (or indeed, FEV1) to gauge the short term clinical response to IV antibiotic
therapy in school-age children with cystic ﬁbrosis.
Crown Copyright © 2014 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.Keywords: Cystic ﬁbrosis; Lung function; Multiple breath washout; Pulmonary exacerbation1. Introduction
Pulmonary disease in children with cystic fibrosis (CF) begins
early in life with lung function abnormalities and bronchiectasis
detected as soon as 3 months [1,2]. Traditional measures of lung
function such as spirometry are often insensitive to the inhomo-
geneous nature of primary lung disease, with forced expiratory
volume in 1 s (FEV1) commonly preserved in the normal range for
the first decade [3]. Despite this, spirometry is still used as the
mainstay of lung function testing to monitor disease progression
and response to therapy in outpatient and inpatient settings.⁎ Corresponding author at: Respiratory Medicine, Royal Children's Hospital
Melbourne, Flemington Road, Parkville 3052, Australia. Tel.: +61 3 9345
5842; fax: +61 3 9345 9154.
E-mail address: Liam.welsh@rch.org.au (L. Welsh).
http://dx.doi.org/10.1016/j.jcf.2014.05.012
1569-1993/Crown Copyright © 2014 Published by Elsevier B.V. on behalf of,EuroMultiple breath washout is now regarded as a more suitable
method to gauge the subtle changes seen in early lung disease
[4] and has the advantage of being applicable to all age-groups.
Though it is well established that lung clearance index (LCI) is
often abnormal in CF, it remains unclear what constitutes a
clinically significant change. This is certainly an important
question for those in the early stages of the disease process,
whichmay be the optimal time to intervene, but it is also pertinent
for those with established disease.
There is currently limited information regarding LCI and its
response to treatment. To date, just three studies have examined
the usefulness of LCI to gauge clinical improvement during
hospital admission following a course of intravenous (IV)
antibiotic therapy [5–7] and a heterogeneous response has been
reported in each. Importantly, only one of these studies has
reported on alveolar phase III indices. Evidently, further data arepean Cystic Fibrosis Society. All rights reserved.
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indices in monitoring acute response to treatment.
The primary aim of this study was to examine the utility of
LCI for assessing short term clinical response to IV antibiotic
therapy in school-age children with CF. Firstly, we hypothesized
that LCI would improve during the admission and secondly, that
LCI would be a clinically useful tool for assessing the therapeutic
benefit of IV antibiotics. Preliminary results of this study have
previously been reported in the form of an abstract [8].Table 1
Clinical demographics of patients.
Subjects 27
Female (%) 15 (56%)
Age (years) 14.7 (6.2; 19.9)
ΔF508 homozygous (%) 13 (48%)
Pseudomonas aeruginosa colonised (%) 9 (33%)
Pancreatic insufficiency (%) 22 (81%)
Diagnosis by newborn screening (%) 17 (63%)
Height z-score −0.05 (0.97)
Weight z-score −0.31 (0.91)
BMI z-score −0.25 (0.83)
Data presented as n, n (%), mean (range) or mean (SD).2. Methods
Between January and December 2013, consecutive patients
with CF who were admitted to the Royal Children's Hospital
(RCH),Melbourne requiring IV therapywere invited to participate.
A pulmonary exacerbation was defined as any change in
symptoms from baseline such as increase or development of
cough, increase in purulent sputum production, or decrease in
exercise tolerance, not responding to outpatient therapy. A
clinical determination was made by the treating physician to
administer IV antibiotics. Patients performed multiple breath
nitrogen washout (MBNW) and spirometry on admission and
prior to discharge. This study was approved by our local human
research ethics committee. Informed consent was obtained from
all patients and/or their parents.
Prior to testing, height was recordedwithout shoes to the nearest
0.1 cm using a fixed stadiometer (Harpenden Stadiometer, Holtain
Ltd, Dyfed, UK) and weight was measured in minimal clothing,
without shoes, to the nearest 0.1 kg using digital scales (Tanita
BWB 600, Tanita Corporation, Tokyo). Height, weight and body
mass index (BMI, i.e. weight/height2), were reported in both raw
form and as z-scores [9].
MBNW was performed using an Exhalyzer D (EcoMedics
AG, Switzerland) running Spiroware version 3.1 software with
the child sitting upright and wearing a nose clip. In brief, each
test consisted of two phases. Following a period of tidal breathing
of ambient air, participants were instructed to maintain their
respiratory rate while breathing 100% oxygen. Each MBNW test
finished when there were three consecutive breaths b1/40th of the
starting nitrogen concentration. A minimum of two satisfactory
LCI results were obtained for each patient. A satisfactory trial was
defined as a regular breathing pattern throughout the test, with no
signs of mouth leak, and functional residual capacity (FRC) values
within 10%. The minimum interval between tests was equal to
washout time. Tests were performed before or at least 2 h after
physiotherapy to avoid any confounding effects on FRC and
thereby LCI. This methodology adheres to the most recently
published consensus statement [10]. LCI was calculated as the
cumulative expired volume required to dilute the end-tidal nitrogen
concentration to 1/40th of the starting concentration divided by
FRC. LCI results were expressed in absolute terms and also as
z-scores [11].
Spirometry was performed using an MS Pneumo spirometer
(Care Fusion, Germany) running SentrySuite version 2.7 software
according to ATS/ERS standards [12] with results expressed as
percent predicted and z-scores [13].The Australian Cystic Fibrosis Data Registry was used to
collect clinical information regarding genotype, newborn screen-
ing status, pancreatic insufficiency, CF related diabetes mellitus,
and Pseudomonas aeruginosa (PsA) infection. Hospital records
were used to determine the length of stay in hospital.3. Statistics
Statistical analysis was performed using Stata Version 12.0
(Stata Corporation, Texas, USA). Paired t-tests were used to
assess the change in lung function parameters over the course
of the hospital admission. To determine whether changes in
lung function outcomes during admission could be explained
by factors other than IV antibiotic therapy, a stepwise regression
model was developed to determine the influence of: sex, age,
genotype (categorized as homozygous ΔF508 versus other/
unknown), newborn screening, body mass index, pancreatic
insufficiency, and PsA infection. Pearson's correlation was used
to measure the magnitude and statistical significance of the
relationship between change in LCI and FEV1 z-scores between
admission and discharge. Significance levels were set at p b 0.05.
LCI z-scores were generated using healthy control data (n = 57)
from Vermeulen et al. [11] which used the same equipment
and included children of a similar age range to our study (i.e.
4–18 years). The mean (SD) for LCI in their control group
was 7.30 (0.50).4. Results
Throughout 2013, we invited 48 children to participate in this
study (4 declined). We collected paired MBNW and spirometry
data from 27 patients (age 6–20 years) with CF on admission and
prior to discharge during their hospital admission. Seventeen
children completed baselinemeasurements only andwere therefore
not included in the analysis, however, they were similar in terms of
sex (59% female), age (14.8 years), LCI z-score (8.7) and FEV1
z-score (−3.16) when compared to the study group. Clinical
demographics are shown in Table 1 and lung function results are
shown in Table 2. Plots of spirometry and lung clearance index on
admission and discharge are shown in Figs. 1 and 2.
The mean (SD) time to test on admission was 1.2 (0.9) days
and mean time of test before discharge was 1.7 (2.5) days. The
Table 2
Lung function on admission and discharge.
Parameter On admission On discharge Actual change (95% CI)
FEV1 (L) 1.88 (0.80) 1.99 (0.89) 0.11 (0.01; 0.22)
a
FEV1 % predicted 63.1 (20.1) 65.5 (20.0) 2.4 (−1.43; 6.21)
FEV1 z-score −3.05 (1.58) −2.86 (1.60) 0.19 (−0.12; 0.50)
FVC (L) 2.60 (0.84) 2.73 (0.94) 0.13 (0.03; 0.23) a
FVC % predicted 76.5 (15.7) 79.6 (16.5) 3.1 (−0.05; 6.34)
FVC z-score −2.02 (1.35) −1.75 (1.42) 0.27 (0.01; 0.55) a
FEV1/FVC ratio 70.8 (14.6) 71.2 (15.7) 0.40 (−2.27; 3.10)
FEV1/FVC z-score −2.00 (1.46) −1.91 (1.61) 0.09 (−0.19; 0.39)
FEF25–75 (L/s) 1.53 (1.19) 1.73 (1.24) 0.20 (0.05; 0.35)
a
FEF25–75 z-score −3.12 (1.69) −2.83 (1.80) 0.32 (0.04; 0.55) a
Lung clearance
index
12.18 (2.98) 11.65 (2.67) −0.53 (−1.16; 0.09)
LCI z-score 9.80 (5.97) 8.70 (5.3) −1.10 (−2.32; 0.18)
Scond 0.043 (0.03) 0.035 (0.02) −0.008 (−0.18; 0.002)
Sacin 0.117 (0.09) 0.084 (0.06) −0.033 (−0.063; −0.003) a
Data are displayed as mean (SD) or mean difference (95% confidence interval).
a p b 0.05.
Fig. 2. Lung clearance index on admission and discharge (p = 0.14). Mean (SD)
was 12.18 (2.98) versus 11.65 (2.67).
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with a mean test interval between admission and discharge of
8.9 (2.9) days.
Overall, n = 15 (55%) patients had a reduction in LCI and
n = 18 (67%) had an improvement in FEV1. However, there
was no significant association between change in LCI z-score
and change in FEV1 z-score (p = 0.84) during the admission
(Fig. 3). FEF25–75 improved significantly throughout the course
of the admission when expressed in absolute terms and as
z-scores (Table 2).
None of sex, age, genotype, newborn screening, body mass
index, pancreatic insufficiency or PsA infection was associated
with the change in LCI during the admission (data not shown).
All patients except one had LCI values that were above the
upper limit of normal for children (i.e. N8.3) at both admission
and discharge [11]. Seven patients (27%) had normal spirometry
(i.e. N−2 z-scores) at admission and eight patients (30%) had
normal spirometry on discharge.Fig. 1. FEV1 z-score on admission and discharge (p = 0.21). Mean (SD) was −3.05
(1.58) versus −2.86 (1.60).5. Discussion
The findings of our study echo those reported previously
with regard to the heterogeneous response of LCI to antibiotic
therapy during pulmonary exacerbations [5–7]. While there
was a dramatic reduction in LCI for some, in many LCI
remained relatively unchanged or even worsened. Overall,
there was only a modest reduction in LCI by 0.53 (4.4%) across
the group. This in is keeping with Horsley et al. who showed a
5.5% reduction in LCI, Robinson et al. (4.8%) and Yammine et al.
(2.2%) [5–7]. Taken together, these results suggest that using LCI
alone to gauge the short term clinical response to IV antibiotic
therapy is inappropriate.
Though the jury may still be out regarding the usefulness of
alveolar phase III indices due to a lack of data, the limited
evidence suggests a similar pattern of heterogeneity. While we
were able to show than Sacin improved significantly and had a
much larger reduction (28%) than LCI, this was primarily driven
by a few significant responders. To further cloud the issue,
Yammine et al. reported no significant difference in Sacin but that
47% of patients had worsened Scond by the end of their tune-up.
Perhaps some other influential factors may be at play such as age,Fig. 3. Change in lung clearance index z-score versus change in FEV1 z-score
(r = 0.04, p = 0.84).
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further longitudinal study this question will remain unanswered.
There are also several other plausible reasons which may help to
explain the heterogeneous response seen in LCI, and indeed
Sacin. In the presence of established lung disease, treatment with
IV antibiotics and intense physiotherapy can lead to the
recruitment of additional lung units not previously involved in
LCI measurement. This may result in an increase in ventilation
inhomogeneity if the time constants of the additional units are
slower, when compared to those previously assessed. This
premise has been neatly demonstrated by noting decreased gas
trapping in patients with significant increases in LCI [5]. In
further support of this, Yammine et al. reported that 58% of the
variability associated with change in LCI could be explained
by changes in gas trapping [7]. Additionally, it is also important
to consider what a patient's LCI may have been like prior to
hospitalisation. Given that LCI is not measured routinely in the
outpatient setting, we do not have longitudinal data to determine
the degree of change in the lead up to admission, or whether any
change was acute or gradual. This type of information would
provide valuable insight with regard to the state of the disease
before hospitalisation. Importantly, a recent study showed that
baseline LCI in children and adolescents with CF predicted the
time to first exacerbation in 12 months after initial assessment.
This may be where the utility of LCI actually sits rather than in
the acute setting [11].
In a similar fashion to LCI, there was also a varied treatment
response observed in FEV1. This is in keeping with several
previous studies which have reported either a lack of improvement
or worsening of FEV1 following IV antibiotic treatment [14–17].
Previous pulmonary exacerbations requiring hospitalisation,
female gender, pancreatic insufficiency, persistent infection with
PsA, and a greater drop from baseline before treatment initiation
have all been associated with a poor response to therapy [14–17].
A third of our patients had PsA infection, and though we did not
find it to significantly influence LCI or FEV outcomes in our
group, this may be a reflection of the study power.
Much of the literature has shown LCI to be a more sensitive
measure of lung disease than spirometry [4,18–21] and our
findings support this. All of our study patients (except one) had
abnormal LCI values throughout their admission, while 27%
and 30% were still considered to have normal spirometry at
admission and discharge, respectively. Though our findings do
not support the use of LCI during treatment of exacerbations, it
may be a useful adjunct in those with mild disease who have
normal spirometry for monitoring progression. This makes
physiological sense when considering what LCI and FEV1 are
actually measuring. FEV1 is more a measure of predominantly
large airway function that can be masked by inhomogeneity of
lung disease, whereas LCI provides information about global
ventilation including the peripheral airways, which is where
early, heterogeneous lung disease begins.
While considering the periphery of the lung, it is important to
note that of all the pulmonary function outcomes we examined,
FEF25–75 was the most responsive to treatment. Both in absolute
terms and when converted to z-scores, FEF25–75 improved
significantly by the time of discharge. It is well recognised thatFEF25–75 is a more sensitive index than FEV1 for detecting small
airway obstruction, however it is often overlooked because it has
a higher degree of variability. Despite the inherent variability
associated with flows versus lung volumes, it does appear to be
better suited to monitoring response to treatment of exacerbations
than even LCI.
While we made every effort in our study to exclude any such
treatment-effect, the influence that physiotherapy has on LCI
measurement remains controversial. While Fuchs et al., concluded
that there was no need to schedule LCI measurements in relation to
physiotherapy sessions in children with CF [22], other reports have
suggested that LCI can change remarkably following physiother-
apy [23]. Importantly, these studies have been performed in a small
number of patients with varying degrees of CF lung disease.
We acknowledge that our study has several limitations. Our
cohort encompassed a broad spectrum of severity which included
patients with mild lung disease through to those in the end-stages.
Though this approach was designed to reveal which classes of
severity were more likely to be responders, the study was probably
underpowered, given the relatively few participants, to adequately
perform such sub-analysis. In addition, we do not have any data
regarding the severity of the admission. Aside from mean length
of stay (range 7–18 days), we are unable to speculate about the
influence that admission severity may have had on treatment
response. As more aggressive treatment generally becomes the
norm, and specific knowledge regarding the detrimental effect of
exacerbations accumulates, decisions to utilize intravenous antibi-
otics in their treatment are probably made for relatively mild
exacerbations compared with the past, with resulting diminished
opportunity to detect improvement in lung function. The interval
between admission and discharge testing may also have been
insufficient to realise the optimal benefit from therapy. A recent
investigation showed that 25% patients never recovered their
baseline lung function following a pulmonary exacerbation and
that it took up to 3 months for some to regain their pre-admission
levels [15]. In view of these findings, perhaps the benefit of IV
antibiotics may not be fully appreciated until a month or more after
discharge. This question requires further exploration. Finally, we
need to acknowledge the 17 children who did not perform
discharge testing. We recognise these data would have benefited
the strength of our study but do not believe it harms the validity,
as the characteristics of these children (including sex, age and
lung function) were similar to the study group. Several children
objected to the length of testing and voiced discomfort regarding
a dry mouth. We believe these were the two key reasons for
children not returning for their discharge appointment.
Despite these shortcomings, our study also has several notable
strengths. Nearly all baseline testing was performed within the
first two days of hospital admission and therefore in sequence
with treatment initiation. As a standard, all testing was performed
either before or at least 2 h after physiotherapy to avoid any
confounding effects on FRC and thereby LCI. Moreover,
follow-up testing was performed just 1.7 days before discharge
to maximize the potential response to therapy.
In summary, although relative change in LCI was slightly
greater than that for FEV when expressed as z-scores, our
findings do not support the use of either to gauge the short term
691L. Welsh et al. / Journal of Cystic Fibrosis 13 (2014) 687–691clinical response to IV antibiotic therapy in school-age children
with cystic fibrosis. Of spirometrymeasurements, closer attention
should be paid to forced mid-expiratory flow measurements.
There appears to be an urgent need to collect longitudinal data in
both inpatient and outpatient settings to better describe the role of
LCI for monitoring response to treatment in relation to baseline.
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